Deep vein thrombosis invasive therapy
 |
Resident Survival Guide |
|
Deep Vein Thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Deep vein thrombosis invasive therapy On the Web |
|
Risk calculators and risk factors for Deep vein thrombosis invasive therapy |
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2] Syed Hassan A. Kazmi BSc, MD [3] Muhammad Saad, M.B.B.S.[4]
Overview
Invasive therapy for deep vein thrombosis (DVT) encompasses catheter-directed thrombolysis (CDT), pharmacomechanical catheter-directed thrombolysis (PCDT), percutaneous mechanical thrombectomy (MT), surgical venous thrombectomy, venous angioplasty and stenting, and inferior vena cava (IVC) filter placement. For most patients with acute DVT, anticoagulation alone remains the standard of care. Invasive therapy is reserved for carefully selected patients with iliofemoral DVT (IFDVT) with severe symptoms, limb-threatening ischemia (phlegmasia cerulea dolens), or established post-thrombotic syndrome (PTS) with iliac vein obstruction. The rationale for invasive therapy centers on the "open vein hypothesis" — the concept that early thrombus clearance and restoration of venous flow may reduce PTS, which affects 20–50% of patients with proximal DVT despite anticoagulation.
Current Guideline Landscape for Invasive DVT Therapy
There is notable guideline disagreement regarding the role of early thrombus removal (ETR) for acute IFDVT. The following table summarizes current major society positions:
| Society / Year | Recommendation | Strength / Grade |
|---|---|---|
| ASH 2020 | Anticoagulation alone over thrombolysis + anticoagulation for most patients with proximal DVT | Conditional; low certainty evidence |
| ACCP/CHEST 2021 | Anticoagulation alone over interventional therapy for acute DVT; exception for limb-threatening DVT (phlegmasia/venous gangrene) | Weak recommendation; moderate certainty |
| ESVS 2021 | Early thrombus removal should be considered for selected patients with symptomatic acute IFDVT (not for femoropopliteal/calf DVT) | Class IIa, Level A |
| SIR 2023 | CDT/PCDT reasonable in carefully selected patients with acute IFDVT; strongly consider for nonelderly patients with moderate-to-severe symptoms and low bleeding risk | Moderate strength; Level of Evidence B |
| NICE 2020 | Consider CDT for symptomatic IFDVT with symptoms <14 days, good functional status, life expectancy ≥1 year, low bleeding risk | — |
| ACR 2020 | Anticoagulation ± CDT/PMT ± stenting usually appropriate for acute IFDVT with moderate-to-severe symptoms <14 days | — |
The ASH and ACCP favor anticoagulation alone for most patients, while the ESVS and SIR support CDT/PCDT in selected patients with symptomatic IFDVT. This disagreement reflects differing interpretations of the same trial data and differing weight given to PTS severity reduction versus overall PTS incidence.[1][2]
Catheter-Directed Thrombolysis (CDT) and Pharmacomechanical Catheter-Directed Thrombolysis (PCDT)
Definitions and Techniques
CDT involves percutaneous catheter placement into the thrombosed venous segment with infusion of a fibrinolytic agent (typically alteplase) directly into the thrombus over 12–24+ hours. PCDT combines fibrinolytic infusion with mechanical thrombus disruption/aspiration devices (e.g., AngioJet rheolytic thrombectomy) in a single session, reducing lytic exposure time and ICU stay.[2]
Evidence From Landmark Randomized Controlled Trials
Three multicenter RCTs have evaluated CDT/PCDT for acute proximal DVT:
CaVenT Trial (2012/2016)
176 patients with first-time IFDVT were randomized to CDT (alteplase) + anticoagulation versus anticoagulation alone. CDT reduced PTS at 2 years (41.1% vs. 55.6%, P=0.047) and at 5 years (43% vs. 71%, P<0.001), but major bleeding occurred only in the CDT group (3 vs. 0). No improvement in generic quality of life was demonstrated.[3]
ATTRACT Trial (2017/2019)
692 patients with acute proximal DVT (iliofemoral or femoropopliteal) were randomized to PCDT + anticoagulation versus anticoagulation alone. In the overall population, PCDT did not reduce PTS incidence (47% vs. 48%; RR 0.96; 95% CI 0.82–1.11; P=0.56) and increased major bleeding (1.7% vs. 0.3%; P=0.049). However, in the prespecified iliofemoral subgroup (n=391), PCDT significantly reduced moderate-to-severe PTS (18% vs. 28%; RR 0.65; P=0.021), reduced severe PTS (Villalta ≥15: 8.7% vs. 15%; RR 0.57; P=0.048; VCSS ≥8: 6.6% vs. 14%; RR 0.46; P=0.013), improved early leg pain and swelling, and improved venous disease-specific quality of life (VEINES-QoL difference 5.6 points; P=0.029) — without a significant increase in major bleeding (1.5% vs. 0.5%; P=0.32). Benefits were not observed in patients with DVT limited to femoropopliteal segments.[4][5]
CAVA Trial (2020/2021)
184 patients with acute IFDVT were randomized to ultrasound-assisted CDT + anticoagulation versus anticoagulation alone. CDT provided no significant reduction in PTS at 1 year using the prespecified Villalta scoring method. At long-term follow-up (median 39 months), a 22% absolute risk reduction in PTS was observed using the ISTH-recommended scoring (OR 0.40; 95% CI 0.19–0.84; P=0.01) but not with the prespecified method (14.2% absolute risk reduction; P=0.11). No QoL improvement was demonstrated. Major bleeding occurred only in the CDT group (5% vs. 0%). A subanalysis showed that UACDT significantly improved iliac vein patency at 12 months (60.3% vs. 25.9%; P=0.002) and long-term (45.2% vs. 11.9%; P<0.001). Absent iliac patency at 12 months was associated with increased PTS risk (OR 10.84; P=0.007), and combined popliteal reflux and absent iliac patency synergistically amplified PTS risk (OR 10.79; P<0.001).[6][7]
Meta-Analytic Data
A meta-analysis of 6 RCTs (1,481 patients) found that catheter-based therapy was not associated with a significant reduction in overall PTS incidence (45.5% vs. 49.8%; P=0.31) but was associated with a trend toward increased major bleeding (4.8% vs. 2.5%; P=0.05).[8] A Cochrane review (2021) found that the thrombolysis group experienced less PTS overall (RR 0.82; 95% CI 0.71–0.94; P=0.006), with a more pronounced effect at late follow-up (>5 years: RR 0.56; 95% CI 0.43–0.73; P<0.0001).[9] A 2025 systematic review focused on IFDVT (20 studies) found that lytic ETR reduced PTS (NNT=6) and moderate-to-severe PTS (NNT=15), but increased major bleeding (NNH=33; OR 4.9; 95% CI 1.3–19.1).[10]
Systemic Thrombolysis
Systemic fibrinolysis improves venous patency (RR 2.48) and reduces PTS (RR 0.54) but substantially increases major bleeding (RR 2.45) and is not recommended for routine DVT management.[11]
Patient Selection for CDT/PCDT
- Based on the SIR 2023 position statement, CDT/PCDT is reasonable in carefully selected patients with acute IFDVT after consideration of:[1]
- Presenting clinical severity (moderate-to-severe symptoms)
- Symptom duration (<14 days preferred)
- Bleeding risk (low risk required)
- Pre-DVT functional capacity
- Age (<65 years more likely to benefit; ≥65 years less likely to benefit and more likely to be harmed)
- Comorbidities and patient preferences
Strongest indication: Phlegmasia cerulea dolens (limb-threatening circulatory compromise) — urgent CDT/PCDT is recommended for limb salvage.[1][2]
Contraindications to CDT/PCDT: Active bleeding, recent major surgery or trauma, recent stroke, intracranial pathology, high bleeding risk, chronic DVT (>21 days for lytic therapy), and pregnancy (relative; limit to compelling indications such as limb threat).[1]
Periprocedural Anticoagulation
The SIR recommends weight-based LMWH (subcutaneous, twice daily) for most ETR candidates because it achieves therapeutic anticoagulation faster than UFH and avoids transitions that create subtherapeutic windows. The safety of concomitant DOACs with fibrinolytic drugs is uncertain. UFH is an alternative but requires active monitoring. During fibrinolytic infusions, patients require close monitoring in a setting that enables timely laboratory assessment and evaluation for bleeding.[1]
Subacute IFDVT
A 2025 study of 86 patients with subacute (15–28 days) IFDVT found that endovascular therapy + anticoagulation provided greater early symptom relief (P<0.001), lower moderate-to-severe PTS at 12 months (6.5% vs. 27.3%; P=0.011), lower Villalta score (3.9 vs. 5.7; P=0.027), and lower VCSS (2.3 vs. 3.6; P=0.004) compared with anticoagulation alone, with no significant differences in bleeding or recurrence.[12]
Percutaneous Mechanical Thrombectomy (MT)
Purely mechanical thrombectomy devices (e.g., ClotTriever, AngioVac) remove thrombus without fibrinolytic agents, potentially eliminating the bleeding risk associated with lytic therapy.
CLOUT Registry
The CLOUT registry is a prospective, multicenter, single-arm study of the ClotTriever System across 43 US sites enrolling 500 patients with lower extremity DVT.[13]
6-month outcomes (500 patients):
- 30-day all-cause mortality: 0.9%; SAE rate: 8.6%; device-related SAE: 0.2%
- SAE rethrombosis: 4.8% at 30 days, 8.0% at 6 months
- Venous flow improved from 27.2% to 92.5% (P<0.0001); compressibility from 28.0% to 91.8% (P<0.0001)
- Median Villalta score improved from 9.0 to 1.0 at 6 months (P<0.0001)[13]
1-year outcomes (310 patients completing visit):
- 1-year PTS rate (Villalta ≥5): 19.3%; moderate-to-severe PTS (Villalta ≥10): 8.8%
- Median Villalta score: 9.0 at baseline to 1.0 at 1 year (P<0.0001)
- Patency: 94.2% of limbs at 1 year
- 90.4% of patients experienced QoL improvements[14]
Outcomes by chronicity (250 patients):
- Complete or near-complete (≥75%) thrombus removal: 90.8% (acute), 81.9% (subacute), 83.8% (chronic)
- No fibrinolytics administered; 99.6% single-session procedures
- 1 device-related SAE (fatal pulmonary embolism, 0.4%)
- No significant differences in outcomes across subgroups[15]
Single-Center Experience
A retrospective review of 81 patients (90 limbs) treated with ClotTriever showed technical success of 98.9%, primary patency at 12 months of 76.2%, median Villalta improvement from 10.5 to 1.0 (P<0.0001), 89.8% PTS-free at follow-up with no moderate/severe PTS, median hospital stay of 1 day, and no major complications or 30-day mortality.[16]
Limitations and Ongoing Trials
- The SIR 2023 position statement notes strong uncertainty about MT's short-term and long-term safety and efficacy, as the hypothesized benefits have not been documented in published prospective studies with control groups and independent outcome assessments. MT outcomes cannot be assumed to resemble those of CDT/PCDT.[1]
- A 2025 meta-analysis found no major bleeding with mechanical thrombectomy (versus OR 4.9 for lytic therapies), but efficacy evidence was limited to a single observational study.[10]
- The DEFIANCE trial (NCT05701917) is an ongoing international RCT comparing ClotTriever-based MT versus anticoagulation alone in approximately 300 patients with unilateral IFDVT (symptom duration ≤12 weeks). The primary endpoint is a hierarchical win ratio of treatment failure/therapy escalation and PTS severity at 6 months. This will be the first RCT to evaluate mechanical thrombectomy versus anticoagulation alone for DVT.[17]
Surgical Venous Thrombectomy
- Open surgical thrombectomy for IFDVT has largely been supplanted by endovascular approaches. The Society for Vascular Surgery (SVS) and American Venous Forum (AVF) 2012 guidelines provide the most recent society-level recommendations on this modality.
- Pooled analysis of older studies showed that surgical thrombectomy reduced PTS (RR 0.67; 95% CI 0.52–0.87) and venous reflux (RR 0.68; 95% CI 0.46–0.99) compared with anticoagulation alone, but data were limited by small sample sizes and lack of blinding.[18]
- Current guidelines suggest surgical thrombectomy primarily for:
- Patients who are candidates for anticoagulation but in whom thrombolytic therapy is contraindicated (SVS/AVF Grade 2C)[18]
- As an alternative to CDT/PCDT in patients with phlegmasia cerulea dolens and elevated bleeding risk[1]
- When endovascular expertise is unavailable and limb-threatening ischemia is present
- Percutaneous thrombolytic approaches are generally favored over surgical thrombectomy when both are feasible.[18]
Venous Angioplasty and Stenting
Acute Setting (After Thrombus Removal)
- If a flow-limiting obstructive lesion is identified in the iliac vein after thrombus debulking with good inflow from leg veins, the SIR recommends stent placement to reduce symptom severity and rethrombosis risk (Moderate strength, Level of Evidence C). Intravascular ultrasound (IVUS) along with venography is suggested to improve assessment of veins after thrombus removal.[1]
- One small RCT found superior 1-year patency with stenting versus no stenting after CDT for IFDVT (74% vs. 47%).[1]
Chronic Setting (Post-Thrombotic Syndrome) — C-TRACT Trial
The C-TRACT trial (N Engl J Med 2026) is a landmark multicenter RCT that randomized 225 patients with moderate-to-severe post-thrombotic syndrome and imaging-confirmed iliac vein obstruction to endovascular therapy (iliac vein stent placement + enhanced antithrombotic therapy) + standard PTS care versus standard care alone.[19]
Key results:
- PTS severity was lower in the stenting group (mean VCSS 8.1±5.1 vs. 10.0±4.9; adjusted difference −2.0; 95% CI −3.2 to −0.8; P=0.001)
- Venous disease-specific QoL improved by 14.5 points (P<0.001)
- SF-36 physical component improved by 6.1 points (P<0.001)
- Bleeding was more common with stenting (11.6% vs. 3.6%; P=0.03)
- This is the first large multicenter RCT to validate iliac vein stenting for established post-thrombotic syndrome, providing Level A evidence for the open vein hypothesis in the chronic setting.[19]
SIR 2023 Position Statement on Chronic Iliofemoral Venous Obstruction With Stents
- The SIR published a separate position statement on the management of chronic iliofemoral venous obstruction with endovascular placement of metallic stents:[20]
- Anticoagulant therapy is recommended for at least several months after stent placement in patients with DVT/PTS history (Level of Evidence D, Strength Moderate)
- Addition of antiplatelet therapy to anticoagulation is appropriate for most PTS patients with low bleeding risk (Level of Evidence D, Strength Weak)
- Close clinical follow-up after stent placement is recommended (Level of Evidence C, Strength Strong)
Antithrombotic Therapy After Venous Stenting
- An international registry of 173 patients with DVT and venous stents found that 63% received anticoagulant-only therapy (DOAC 29%, warfarin 22%, LMWH 10%), while 34% received combined anticoagulant-antiplatelet therapy. Factors associated with combined therapy included use of thrombolytic/thrombectomy/aspiration (OR 5.11), balloon angioplasty (OR 2.62), and immediate stent restenosis (OR 7.2). Optimal post-stenting antithrombotic regimens remain uncertain.[21]
- An expert panel narrative review (2022) recommended that post-interventional antithrombotic therapy for thrombotic disorders should adhere to VTE management guidelines (3–6 months minimum), with the added benefit of antiplatelet agents unknown and dual/triple therapy limited based on individual risk.[22]
Inferior Vena Cava (IVC) Filters
The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism provides the most current recommendations on IVC filters:[23][24]
Indications
| Class 1 (Strong) |
| 1. Retrievable IVC filter placement is recommended for patients with acute proximal DVT or PE who cannot receive anticoagulation. Retrievable filters are preferred over permanent filters. |
| Class 3: No Benefit |
| 1. Routine IVC filter placement in patients who can receive anticoagulation offers no clinical benefit. The PREPIC2 trial found no additional benefit of IVC filter placement in anticoagulated patients. |
Risks and Complications
IVC filters reduce PE recurrence by approximately 50% but increase DVT risk by approximately 70%, with no mortality benefit. Complications include strut fracture, migration, IVC perforation, and thrombosis.[23][8]
Filter Retrieval
The FDA recommends retrieval within 29–54 days once PE risk has subsided. Challenging retrievals are more common after 50 days; failed retrievals after 90 days. Structured follow-up programs significantly improve retrieval rates. Permanent filters should be reserved for rare cases where retrievable filters are not feasible (e.g., mega cava >30 mm).[23][24]
2025 AHA Scientific Statement: Revisiting the Open Vein Hypothesis
The 2025 AHA Scientific Statement reframes the open vein hypothesis, emphasizing that freedom from PTS requires not just initial thrombus clearance but long-term venous patency, reduced recurrent thrombosis, and reduced perithrombotic inflammation. The statement proposes a multidisciplinary care model for IFDVT and highlights that contemporary modalities (DOACs, IVUS, dedicated venous stents) were not routinely used in the 3 major RCTs (CaVenT, ATTRACT, CAVA). Priority research areas include biomarker-guided therapy and advanced imaging.[3]
2011 AHA Scientific Statement-Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension (DO NOT EDIT)[25]
Recommendations for Endovascular Thrombolysis and Surgical Venous Thrombectomy (DO NOT EDIT)[25]
| Class III (No Benefit) |
| "1. Systemic fibrinolysis should not be given routinely to patients with IFDVT (Level of Evidence: A)." |
| "2. CDT or PCDT should not be given to most patients with chronic DVT symptoms (>21 days) or patients who are at high risk for bleeding complications (Level of Evidence: B)." |
| Class I |
| "1. CDT or PCDT should be given to patients with IFDVT associated with limb-threatening circulatory compromise (ie, phlegmasia cerulea dolens) (Level of Evidence: C)." |
| "2. Patients with IFDVT at centers that lack endovascular thrombolysis should be considered for transfer to a center with this expertise if indications for endovascular thrombolysis are present (Level of Evidence: C)." |
| Class IIa |
| "1. CDT or PCDT is reasonable for patients with IFDVT associated with rapid thrombus extension despite anticoagulation (Level of Evidence: C) and/or symptomatic deterioration from the IFDVT despite anticoagulation (Level of Evidence: B)." |
| "2. CDT or PCDT is reasonable as first-line treatment of patients with acute IFDVT to prevent PTS in selected patients at low risk of bleeding complications (Level of Evidence: B)." |
Recommendations for Percutaneous Transluminal Venous Angioplasty and Stenting (DO NOT EDIT)[25]
| Class IIa |
| "1. Stent placement in the iliac vein to treat obstructive lesions after CDT, PCDT, or surgical venous thrombectomy is reasonable (Level of Evidence: C)." |
| "2. For isolated obstructive lesions in the common femoral vein, a trial of percutaneous transluminal angioplasty without stenting is reasonable (Level of Evidence: C)." |
| "3. The placement of iliac vein stents to reduce PTS symptoms and heal venous ulcers in patients with advanced PTS and iliac vein obstruction is reasonable (Level of Evidence: C)" |
| "4. After venous stent placement, the use of therapeutic anticoagulation with similar dosing, monitoring, and duration as for IFDVT patients without stents is reasonable (Level of Evidence: C)" |
| Class IIb |
| "1. After venous stent placement, the use of antiplatelet therapy with concomitant anticoagulation in patients perceived to be at high risk of rethrombosis may be considered (Level of Evidence: C) " |
High-Yield Clinical Pearls
Anticoagulation first, always. Consideration of early thrombus removal should never delay achievement of fully therapeutic anticoagulation.[1]
IFDVT ≠ femoropopliteal DVT for invasive therapy decisions. The ATTRACT trial showed benefit only in the iliofemoral subgroup; patients with DVT limited to femoropopliteal segments did not benefit from PCDT.[5]
Phlegmasia cerulea dolens is the one scenario with near-universal agreement for urgent invasive intervention (CDT/PCDT, MT, or surgical thrombectomy).[1][2]
Symptom duration <14 days is the preferred window for CDT/PCDT; beyond 14 days, complete lysis is unlikely with CDT/PCDT alone.[1]
IVC filters are not a substitute for anticoagulation. Anticoagulation should be initiated as soon as feasible, and the filter retrieved promptly.[23]
C-TRACT validates iliac vein stenting for PTS — the first large RCT to show benefit of endovascular therapy for established post-thrombotic syndrome.[19]
Mechanical thrombectomy is increasingly used but lacks RCT evidence; the DEFIANCE trial will provide the first randomized data.[1][17]
Common Pitfalls
Performing CDT/PCDT for femoropopliteal DVT without iliofemoral involvement — no evidence of benefit and increased bleeding risk.[4][5]
Delaying anticoagulation while arranging invasive therapy — therapeutic anticoagulation is the highest priority.[1]
Failing to retrieve IVC filters once anticoagulation is feasible — retrieval becomes progressively more difficult after 50 days and filter complications accumulate over time.[23]
Assuming mechanical thrombectomy outcomes are equivalent to CDT/PCDT — different devices may variably influence thrombus clearance, vein wall injury, and long-term outcomes; RCT data are lacking.[1]
Offering CDT/PCDT to elderly patients (≥65 years) without careful risk-benefit discussion — this group is less likely to benefit and more likely to experience harm.[1]
Using DOACs concurrently with fibrinolytic infusions — safety of this combination is uncertain; LMWH or UFH is preferred periprocedurally.[1]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 Vedantham S, Desai KR, Weinberg I, Desai NR, Goldhaber SZ, Goldhaber SZ (2023). "Society of Interventional Radiology Position Statement on the Endovascular Management of Acute Iliofemoral Deep Vein Thrombosis". J Vasc Interv Radiol. 34 (2): 153–160. doi:10.1016/j.jvir.2022.10.029. PMID 36481263 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 Expert Panel on Interventional R, Farsad K, Kapoor BS, Defined JR, defined JR (2020). "ACR Appropriateness Criteria Radiologic Management of Iliofemoral Venous Thrombosis". J Am Coll Radiol. 17 (5S): S152–S163. doi:10.1016/j.jacr.2020.01.028. PMID 32370957 Check
|pmid=value (help). Vancouver style error: initials (help) - ↑ 3.0 3.1 Li W, Vedantham S, Jaffer FA, Kahn SR, Goldhaber SZ, Piazza G, Defined JR (2025). "Revisiting the Open Vein Hypothesis to Reduce the Postthrombotic Syndrome: Implications for Multidisciplinary Care and Research: A Scientific Statement From the American Heart Association". Circulation. 151. doi:10.1161/CIR.0000000000001310. PMID 39882614 Check
|pmid=value (help). - ↑ 4.0 4.1 Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filber M, Gu CS, Kuo WT, Lookstein R, Moll S, Sacks D, Defined JR (2017). "Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis". N Engl J Med. 377 (23): 2240–2252. doi:10.1056/NEJMoa1615066. PMID 29211671.
- ↑ 5.0 5.1 5.2 Comerota AJ, Kearon C, Gu CS, Julian JA, Goldhaber SZ, Kahn SR, Jaff MR, Razavi MK, Defined JR (2019). "Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis". Circulation. 139 (9): 1162–1173. doi:10.1161/CIRCULATIONAHA.118.037425. PMID 30586751.
- ↑ Notten P, de Smet A, Tick LW, Arnoldussen C, Strijkers R, Defined JR (2021). "CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis on Preventing Post-Thrombotic Syndrome) Trial: Long-Term Follow-Up Results". J Am Heart Assoc. 10 (11): e018973. doi:10.1161/JAHA.120.018973. PMID 34032127 Check
|pmid=value (help). Vancouver style error: initials (help) - ↑ Hupperetz RD, Iding A, van Laanen J, Defined JR (2024). "Patency and Reflux in Relation to Postthrombotic Syndrome: A Subanalysis of the Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome Trial". J Thromb Haemost. 22 (12). doi:10.1016/j.jtha.2024.08.015. PMID 39299612 Check
|pmid=value (help). Vancouver style error: initials (help) - ↑ 8.0 8.1 Chopard R, Albertsen IE, Piazza G (2020). "Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review". JAMA. 324 (17): 1765–1776. doi:10.1001/jama.2020.17272. PMID 33170239 Check
|pmid=value (help). - ↑ Broderick C, Watson L, Armon MP (2021). "Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb". Cochrane Database Syst Rev. 1: CD002783. doi:10.1002/14651858.CD002783.pub5. PMID 33464575 Check
|pmid=value (help). - ↑ 10.0 10.1 Turner B, Jasionowska S, Shea J, Defined JR (2025). "A Systematic Review and Meta-Analysis of the Efficacy and Safety of Lytic and Non-Lytic Early Thrombus Removal Technologies for Iliofemoral Deep Vein Thrombosis". Ann Surg. PMID 40421786 Check
|pmid=value (help). Vancouver style error: initials (help) - ↑ Rashedi S, Leyva H, Hamade N, Defined JR (2025). "Fibrinolytic Therapy for Thromboembolic Diseases: Approved Indications and Future Directions". J Am Coll Cardiol.
- ↑ Huang Q, Zhang X, Zhang L, Defined JR (2025). "Endovascular Therapy Versus Anticoagulation Alone for Subacute Iliofemoral Deep Vein Thrombosis". J Vasc Interv Radiol. 36 (4). doi:10.1016/j.jvir.2024.12.017. PMID 39732332 Check
|pmid=value (help). - ↑ 13.0 13.1 Shaikh A, Zybulewski A, Paulisin J, Defined JR (2023). "Six-Month Outcomes of Mechanical Thrombectomy for Treating Deep Vein Thrombosis: Analysis From the 500-Patient CLOUT Registry". Cardiovasc Intervent Radiol. 46 (11): 1537–1547. doi:10.1007/s00270-023-03519-8. PMID 37580422 Check
|pmid=value (help). - ↑ Bisharat MB, Ichinose EJ, Veerina KK, Defined JR (2024). "One-Year Clinical Outcomes Following Mechanical Thrombectomy for Deep Vein Thrombosis: A CLOUT Registry Analysis". J Soc Cardiovasc Angiogr Interv. 3 (3): 101307. doi:10.1016/j.jscai.2024.101307. PMID 39131784 Check
|pmid=value (help). - ↑ Abramowitz SD, Kado H, Schor J, Defined JR (2023). "Six-Month Deep Vein Thrombosis Outcomes by Chronicity: Analysis of the Real-World ClotTriever Outcomes Registry". J Vasc Interv Radiol. 34 (5): 822–830. doi:10.1016/j.jvir.2023.01.016. PMID 37105663 Check
|pmid=value (help). - ↑ Qamhawi Z, Braithwaite S, Ahmed R, Defined JR (2025). "Mechanical Thrombectomy for the Treatment of Iliofemoral Deep Venous Thrombosis Using the ClotTriever System: A Single-Centre Experience". Cardiovasc Intervent Radiol. PMID 40640411 Check
|pmid=value (help). - ↑ 17.0 17.1 Abramowitz SD, Marko X, D'Souza D, Defined JR (2025). "Rationale and Design of the DEFIANCE Study: A Randomized Controlled Trial of Mechanical Thrombectomy Versus Anticoagulation Alone for Iliofemoral Deep Vein Thrombosis". Am Heart J. 281: 1–10. doi:10.1016/j.ahj.2024.11.010. PMID 39491572 Check
|pmid=value (help). - ↑ 18.0 18.1 18.2 Meissner MH, Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Lohr JM, McLafferty RB, Murad MH, Padberg F, Pappas P, Raffetto JD, Wakefield TW (2012). "Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum". J Vasc Surg. 55 (5): 1449–1462. doi:10.1016/j.jvs.2011.12.081. PMID 22169668.
- ↑ 19.0 19.1 19.2 Vedantham S, Kahn SR, Marston WA, Defined JR (2026). "Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial". N Engl J Med. 394 (7). doi:10.1056/NEJMoa2409498. PMID 39907455 Check
|pmid=value (help). - ↑ Vedantham S, Weinberg I, Desai KR, Defined JR (2023). "Society of Interventional Radiology Position Statement on the Management of Chronic Iliofemoral Venous Obstruction With Endovascular Placement of Metallic Stents". J Vasc Interv Radiol. 34 (11): 1891–1897. doi:10.1016/j.jvir.2023.07.024. PMID 37573260 Check
|pmid=value (help). - ↑ Lee Cervi A, Applegate D, Stevens SM, Defined JR (2023). "Antithrombotic Management of Patients With Deep Vein Thrombosis and Venous Stents: An International Registry". J Thromb Haemost. 21 (12): 3459–3468. doi:10.1016/j.jtha.2023.09.020. PMID 37739038 Check
|pmid=value (help). - ↑ Kishore S, Khaja MS, Thornburg B, Defined JR (2022). "Antithrombotic Therapy After Venous Interventions: Expert Panel Narrative Review". AJR Am J Roentgenol. 219 (3): 357–366. doi:10.2214/AJR.22.27476. PMID 35352572 Check
|pmid=value (help). - ↑ 23.0 23.1 23.2 23.3 23.4 Creager MA, Barnes GD, Giri J, Defined JR (2026). "2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults". Circulation. doi:10.1161/CIR.0000000000001309. PMID 39969413 Check
|pmid=value (help). - ↑ 24.0 24.1 Creager MA, Barnes GD, Giri J, Defined JR (2026). "2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults". J Am Coll Cardiol. doi:10.1016/j.jacc.2025.01.025. PMID 39969414 Check
|pmid=value (help). - ↑ 25.0 25.1 25.2 Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ; et al. (2011). "Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association". Circulation. 123 (16): 1788–830. doi:10.1161/CIR.0b013e318214914f. PMID 21422387.